[
  {
    "ts": null,
    "headline": "Johnson & Johnson: Q4 Earnings May Not Prompt Sustained Directional Moves",
    "summary": "Johnson & Johnson has underperformed its lerge-cap healthcare peers and the S&P 500, with an -8% decline over the past year. Read my JNJ earnings preview.",
    "url": "https://finnhub.io/api/news?id=191aa74c86baf16d21f87696d693298aebe548ce810a2ade9f5bfb5184359083",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737026944,
      "headline": "Johnson & Johnson: Q4 Earnings May Not Prompt Sustained Directional Moves",
      "id": 132406527,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1180491673/image_1180491673.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson has underperformed its lerge-cap healthcare peers and the S&P 500, with an -8% decline over the past year. Read my JNJ earnings preview.",
      "url": "https://finnhub.io/api/news?id=191aa74c86baf16d21f87696d693298aebe548ce810a2ade9f5bfb5184359083"
    }
  },
  {
    "ts": null,
    "headline": "RYBREVANT速 plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancer",
    "summary": "Phase 3 MARIPOSA-2 study showed RYBREVANT速 in combination with carboplatin and pemetrexed significantly improved progression-free survival compared to carboplatin and pemetrexed alone.1TORONTO, Jan....",
    "url": "https://finnhub.io/api/news?id=f40a26a74400d858abb9b5e6c19f1bfead53d7e18956e26bde6385a9eb5aa0ba",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737018726,
      "headline": "RYBREVANT速 plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancer",
      "id": 132405829,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Phase 3 MARIPOSA-2 study showed RYBREVANT速 in combination with carboplatin and pemetrexed significantly improved progression-free survival compared to carboplatin and pemetrexed alone.1TORONTO, Jan....",
      "url": "https://finnhub.io/api/news?id=f40a26a74400d858abb9b5e6c19f1bfead53d7e18956e26bde6385a9eb5aa0ba"
    }
  },
  {
    "ts": null,
    "headline": "The Near-Perfect Dividend Portfolio With 10 Sleep-Well-At-Night Gems",
    "summary": "The Near-Perfect Dividend Portfolio With 10 Sleep-Well-At-Night Gems",
    "url": "https://finnhub.io/api/news?id=5e0c411f9de2843b78a5b97dcf88016ff7b1090acda1e12e74f0b9cdde168eb0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737012600,
      "headline": "The Near-Perfect Dividend Portfolio With 10 Sleep-Well-At-Night Gems",
      "id": 132405336,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=5e0c411f9de2843b78a5b97dcf88016ff7b1090acda1e12e74f0b9cdde168eb0"
    }
  },
  {
    "ts": null,
    "headline": "Tempering Positive Sentiment Of AI In Biotech",
    "summary": "AI optimizes existing knowledge but doesn't expedite drug approval or reduce costs compared to traditional methods. Explore more details here.",
    "url": "https://finnhub.io/api/news?id=cd2ce10465b2022ad38901994024c990f366b0e2333aac6670be174216a19808",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737007436,
      "headline": "Tempering Positive Sentiment Of AI In Biotech",
      "id": 132404884,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2163707266/image_2163707266.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "AI optimizes existing knowledge but doesn't expedite drug approval or reduce costs compared to traditional methods. Explore more details here.",
      "url": "https://finnhub.io/api/news?id=cd2ce10465b2022ad38901994024c990f366b0e2333aac6670be174216a19808"
    }
  },
  {
    "ts": null,
    "headline": "Companies From Afar Tap Houston Bankruptcy Court Despite Minimal Local Ties",
    "summary": "Companies From Afar Tap Houston Bankruptcy Court Despite Minimal Local Ties",
    "url": "https://finnhub.io/api/news?id=80448512f1920a49867f22d8335de52c4bfd338d254d038b42ab3f8774cb7342",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737005400,
      "headline": "Companies From Afar Tap Houston Bankruptcy Court Despite Minimal Local Ties",
      "id": 132459217,
      "image": "",
      "related": "JNJ",
      "source": "DowJones",
      "summary": "Companies From Afar Tap Houston Bankruptcy Court Despite Minimal Local Ties",
      "url": "https://finnhub.io/api/news?id=80448512f1920a49867f22d8335de52c4bfd338d254d038b42ab3f8774cb7342"
    }
  }
]